The Michael J. Fox Foundation (MJFF) has released a new guide that aims to help people with Parkinson’s disease and their loved ones make informed decisions about deep brain stimulation (DBS), a surgical treatment for the disorder’s motor symptoms. The 22-page guide, which is freely available online,…
News
Servier and Oncodesign have selected a LRRK2 inhibitor as their partnership program’s lead candidate for Parkinson’s disease and plan to start regulatory preclinical safety studies soon. A Phase 1 clinical trial is expected to begin in 2022. “We are particularly pleased with, and proud of, these results obtained…
In Parkinson’s disease, DNA that leaks out of mitochondria — small organelles that generate energy — leads to cell death and inflammation, according to a new study. The finding indicates that getting rid of this mitochondrial DNA could be a promising therapeutic strategy. The study, “Cytosolic dsDNA of…
The asymmetric loss of dopamine-producing, or dopaminergic, neurons in the brains of people with Parkinson’s disease may determine the severity of patients’ motor and cognitive symptoms, a study suggests. Such differences in the loss of these dopaminergic neurons — a characteristic feature of Parkinson’s — may explain the contrast…
Two years of continuous treatment with apomorphine as an under-the-skin infusion safely preserved quality of life and effectively eased motor fluctuations in people with advanced Parkinson’s disease, according to a single-center, real-life study in France. Notably, patients with poor life quality before starting with continuous apomorphine were more likely to improve in…
Gut inflammation could play a critical role in the onset and progression of Parkinson’s disease, a preclinical study shows. Specifically, this type of inflammation triggered the accumulation of alpha-synuclein protein clumps in the nerves lining the colon of a mouse model of…
Caraway Therapeutics is partnering with AbbVie to develop and market Caraway’s small molecule therapies targeting TMEM175, a potassium ion channel implicated in Parkinson’s disease and other neurodegenerative disorders. TMEM175 is present in lysosomes — tiny compartments in cells containing enzymes that break down unwanted cell parts, digesting and…
One month of non-invasive vagus nerve stimulation (nVNS), administered at home using a hand-held device by electroCore, improved walking and motor abilities, and eased freezing of gait in adults with Parkinson’s disease, according to data from a small clinical trial. Freezing of gait refers to a patient’s feeling for…
The U.S. Food and Drug Administration (FDA) has rejected an application from Verily Life Sciences that sought to add a Parkinson’s disease symptom assessment tool to the company’s clinical research-focused smartwatch. In its response letter, the FDA said there was not enough evidence that the criteria evaluated…
Oral doses of silibinin — a plant compound sold as a dietary supplement — were found to lessen cognitive impairment in a mouse model of Parkinson’s disease. It worked, according to researchers, by preventing neurodegeneration in the hippocampus, a brain region associated with cognitive function. These neuroprotective effects…
Recent Posts
- Deep brain stimulation was a lifesaver for my husband with Parkinson’s
- Me and Mary Jane: My one experience trying marijuana for Parkinson’s
- Low muscle mass is more common in early-stage Parkinson’s disease
- Guest Voice: What de facto parenting can teach us about Parkinson’s
- Parkinson’s advocates urge implementation of new federal plan